Journal
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
Volume 29, Issue 9, Pages 1336-1341Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/ATVBAHA.109.192088
Keywords
nevirapine; high-density lipoprotein cholesterol; apolipoprotein A-I; metabolism; stable isotopes
Categories
Funding
- Boehringer Ingelheim
Ask authors/readers for more resources
Objective-The purpose of this study was to investigate the mechanism by which the nonnucleoside reverse transcriptase inhibitor (NNRTI) nevirapine (NVP) increases high-density lipoprotein cholesterol (HDLc) in treatment-experienced human immunodeficiency virus-1 (HIV-1)-infected patients. Methods and Results-Twelve HIV-1 infected patients, with stably suppressed HIV-1 viral load using AZT/3TC/abacavir for >= 6 months, added NVP to their current antiretroviral regimen. Patients received a primed bolus infusion of the stable isotope L-[1-C-13]-valine for 12 hours before, as well as 6 and 24 weeks after, the addition of NVP to study apolipoprotein A-I (apoA-I) kinetics. Absolute production rate (APR) and fractional catabolic rate (FCR) of apoA-I were calculated using SAAM-II modeling. Major HDLc-modulating enzymes were assessed. Plasma apoA-I and HDLc levels increased significantly after 24 weeks of treatment by, respectively, 13 +/- 4% (P=0.01) and 16 +/- 6% (P=0.015). Concomitantly, apoA-I production rate at 24 weeks increased by 17 +/- 7% (P=0.04). ApoA-I catabolism did not change. A modest increase of lecithin: cholesterol acyltransferase and cholesteryl ester transfer protein activity was observed. Conclusions-NVP increases apoA-I production, which contributes to the HDLc increase after introduction of NVP-containing regimens. In view of the potent antiatherogenic effects of apoA-I, the observed increase may contribute to the favorable cardiovascular profile of NVP. (Arterioscler Thromb Vasc Biol. 2009;29:1336-1341.)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available